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Abstract
Introduction: mtDNA defects, both deletions and point mutations, have been
associated with hypertrophic cardiomyopathies. The aim of this study was to
establish a spectrum for mtDNA mutations in Iranian hypertrophic cardio  -
myopathy (HCM) patients. 
Material and methods: The control group was chosen among the special medical
centre visitors who did not have hypertrophic cardiomyopathy or any related
heart disease. Hypertrophic cardiomyopathy (HCM) is widely accepted as
a pluricausal or multifactorial disease. Because of the linkage between energy
metabolism in the mitochondria and cardiac muscle contraction, it is reasonable
to assume that mitochondrial abnormalities may be responsible for some forms
of HCM. Point mutations and deletions in the two hot spot regions of mtDNA
were investigated by PCR and sequencing methods.
Results: Some unreported point mutations have been found in this study but
no deletion was detected. Meanwhile some of these point mutations have been
investigated among HCM patients for the first time.
Conclusions: A8860G transition was detected in a high proportion, raising the
question whether this rare polymorphism is associated as a secondary effect
in HCM disease.
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Introduction
The cardiomyopathies are a clinically and genetically heterogeneous
group of cardiac diseases in which the myocardium is primarily involved.
Three distinct categories of cardiomyopathy can be classified by functional
and pathological criteria: hypertrophic cardiomyopathy (HCM), dilated
cardiomyopathy (DCM) and restrictive cardiomyopathy. It has been
proposed that approximately 45-50% of familial hypertrophic cardio  -
myopathy cases are due to mutations in genes encoding contractile
proteins of the sarcomere including the á-cardiac myosin heavy chain gene,
the cardiac troponin T gene and the á-tropomyosin gene. 
It is now known that hypertrophic cardiomyopathy can occur as a result
of point mutations in the highly conserved transfer RNA genes of
mitochondrial DNA. The mitochondrial genome, exclusively inherited
through the maternal line, is a 16.5 kilobase (kb), circular, double stranded
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molecule that encodes two ribosomal RNAs, 22
transfer RNAs and 13 proteins involved in the
mitochondrial respiratory chain and oxidative
phosphorylation system. The oxidative phospho  -
rylation system is fundamental to the synthesis of
cellular ATP and consequently pathogenic
mutations of mitochondrial DNA are believed to
cause disease by impairing the function of the
mitochondrial respiratory chain and oxidative
phosphorylation system, thereby decreasing cellular
ATP synthesis. 
Mitochondrial DNA point mutations have been
identified in a broad spectrum of clinical
phenotypes. The majority of these are associated
with neurological disorders such as the mito  -
chondrial myopathies and encephalo  myo  pathies,
although a number of mitochondrial DNA point
mutations have been reported in patients with
hypertrophic cardiomyopathy, either alone or as
part of a multisystem disorder [1]. In this study we
investigated point mutation diversities in the two
hot spot regions of mitochondrial DNA among
Iranian HCM patients.
Material and methods
Patients
A total of 31 hypertrophic cardiomyopathic adult
patients of unrelated families were selected based
on their medical examination, electrocardiogram,
Holter monitoring, and angiography [2]. All of the
patients were informed regarding the aims of the
study and gave their consent for genetic analysis.
The control group consisted of 100 visitors of the
special medical centre who were chosen among the
visitors without hypertrophic cardiomyopathic
disease or any related heart disease and with no
family history of this disease. 
DNA extraction
Genomic DNA was extracted from 5 ml of
peripheral blood using a DNA extraction kit (Diatom
DNA Extraction Kit, Genefanavaran, Tehran, Iran). 
mtDNA deletion analysis
We screened the 31 HCM patients for mtDNA
deletions according to previous work carried out by
Houshmand et al. The PCRs were performed in 
35 cycles composed of the following steps: 94°C for
1 min, 55°C for 1 min and 72°C for 35 s. The deletion-
prone region between nt5461 of the light strand and
nt 15000 of the heavy strand was investigated in all
patients using the primers ONP 86, ONP 89, ONP10,
ONP 74, ONP 25 and ONP 99 (Table I). The distances
between the primers were long enough to allow
amplification only if a part of the DNA between the
respective primers was deleted. The primer pair ONP
86/ONP 89 was used to amplify a normal internal
mtDNA fragment in a region which is seldom afflicted
by deletions, thus serving as a control in the PCR
analysis. We categorized mtDNA deletions into 
4 classes of A, B, C, and D corresponding to 8.7-, 7.5-,
5- and 7.5-kb deletions, respectively (Table II) [3]. 
PCR sequencing
The first mtDNA region from nt 1441 to nt 6001
including RNR2, TL1, ND1, TQ, ND2 and the second
region (1,635 bp) from nt 7377 to nt 9031 that
includes CO2 and ATP6 were amplified according to
the method by Ahari et al. [4]. 
ONP 86 (LF): 5461–5480 (ND2) 5’-CCC TTA CCA CGC TAC TCC TA-3’
ONP 89 (HB): 5740–5721 (OL) 5’-GGC GGG AGA AGT TTG AA-3’
ONP 10 (HB): 15000–14981 (Cytb) 5’-TTG GCG TGA AGG TAG CGG AT-3’
ONP 74 (HB): 13640–13621 (ND50) 5’-GGT TGA CCT GTT AGG GTG AG-3’
ONP 25 (LF): 8161–8180 (COII) 5’-CTA CGG TCA ATG CTC TGA AA-3’
ONP 99 (HB): 16150–16131 (D-loop) 5’-GTG GTC AAG TAT TTA TGG TA-3’
Table I. Primers used for mtDNA deletion analysis
Primers Starting point Ending point Deletion length [Kb] PCR product length [bp] Deletion
ONP 86, ONP 10 5461 15000 8.7 500 A
ONP 86, ONP 74 5461 13640 7.5 680 B
ONP 25, ONP 74 8180 13640 5 420 C
ONP 25, ONP 99 8180 16150 7.5 970 D
ONP 86, ONP 89 5461 5740 – 279 Internal control
Table II. Primers used for detection of 4 deletions
LF – forward primer, HB – reverse primer
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PCR products were checked on 1% agarose gel.
MtDNA sequencing was done by using forward and
reverse primers (Table III) to detect novel mutations
that might impair mitochondrial protein synthesis
in the two hot spot regions by a 3700 ABI
sequencer (Macrogene Korea). The obtained mtDNA
sequences were aligned with a multiple sequence
alignment interface CLUSTAL_X and then compared
with the reference sequence [5]. MITOMAP: MtDNA
Coding Region Sequence Polymorphisms web site
was used for investigation and comparison of
detected mutations for final conclusions [6].
Results
In the first step no mtDNA deletion was found
among the cases. After that samples from all 31
patients were forwarded for sequencing analysis
of the two hot spot regions in mtDNA that included
RNR2, TL1, ND1, TQ, ND2, CO2 and ATP6 segments. 
Altogether 43 point mutational polymorphisms
were found in this study; 10 unpublished
polymorphisms were found among them. This
finding demonstrates the high variability of human
mtDNA. The rest of the polymorphisms have been
reported before. No previously reported disease-
causing mutations of mtDNA were found within the
sequenced regions of participants (Table IV). 
Some of these novel base substitutions do not
lead to amino acid exchange and are consequently
defined as polymorphisms, such as T1700C. The
second group of sequence alterations can be
divided into two classes: 1) conservative exchanges,
leading to substitution by a homologous amino
acid, such as A5480G, and 2) non-homologous
substitutions, such as G5466A.
An apparently homoplasmic substitution within
tRNA genes was found: T4384C, which affects the
T_C loop of tRNA glutamine. No other point
mutation was found among the studied
mitochondrial tRNA genes.
Except for 3 remarkable mutations (A8860G,
A2706G and N3107C) most of these polymorphisms
were observed among fewer than 5 patients 
(Table IV).
Discussion 
During the past decade, more than 100
mutations in 11 causal genes coding for sarcomeric
proteins, the γ subunit of AMP-activated protein
kinase and triplet-repeat syndromes and in
mitochondrial DNA, have been identified in patients
with hypertrophic cardiomyopathy (HCM). Genotype-
phenotype correlation studies show significant
variability in the phenotype expression of HCM
among affected individuals with identical causal
mutations. Overall, causal mutations account for
a fraction of the variability of phenotypes, and the
genetic background, referred to as the modifier
genes, plays a significant role. The final phenotype
is the result of interactions between the causal
genes, the genetic background (modifier genes),
and probably environmental factors. The individual
modifier genes for HCM remain largely unknown,
so a large-scale genome-wide approach and
candidate gene analysis are needed [7].
Recently, maternally inherited forms of HCM
have been associated with defects in oxidative
metabolism that are primarily due to alterations in
mtDNA, such as deletions and various point
mutations [8-10]. But in fact we did not find any
deletion in our study. 
Previously, a variety of neurodegenerative and
neuromuscular diseases that demonstrate strict
maternal inheritance have been attributed to single
point mutations in mtDNA. The best characterized
examples include MELAS (mitochondrial myopathy,
encephalopathy, lactic acidosis, and stroke-like
episodes) and MERRF (myoclonic epilepsy and
ragged red fibres) [11-15]. 
Point mutations in tRNA genes have also been
attributed to maternally inherited forms of sudden
cardiopulmonary arrest and HC. Mutations in
mtDNA that lead to HC include A-to-G and C-to-T
transitions at nucleotide 3260 and nucleotide 3303,
respectively, in tRNALeU(UUR); A-to-G transitions
at nucleotide 4317 and nucleotide 4266 in tRNAIle;
and, possibly, an A-to-G transition at nucleotide
15951 in tRNAThr. A novel point mutation (T to C)
was found in the mitochondrial tRNAgly gene at
F60 1441-1460 5’-AGT AGA GTG CTT AGT TGA GC-3’
R63 3140-3121 5’-TCT CTT GTC CTT TCG TAC AG-3’
F62 3001-3020 5’-GGA CAT CCC GAT GGT GCA GC-3’
R65 4650-4631 5’-GGA AAT ACT TGA TGG CAG CT-3
F64 4491-4540 5’-GTC ATC TAC TCT ACC TAC TT-3’
R67 6020-6001 5’-GGC TCG AAT AAG GAG GCT TA-3’
F21 7377-7396 5’-CTG GAG TGA CTA TAT GGA TG-3’
R56 9050-9031 5’-CCA AAT AGG TGC ATG AGT AG-3’
Table III. Primers used for mtDNA sequencing
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Locus Nucleotide  Frequency Nucleotide  Amino acid  Reported in MitoMap 
position (31 patients) change changer e ferences
RNR2 1700 1 T-C Non-coding +
1718 1 A-AA Non-coding +
1719 1 G-A Non-coding *+
1810 1 A-G Non-coding Unpublished
1811 2 A-G Non-coding +
1888 2 G-A Non-coding +
1977 1 T-C Non-coding *+
2071 1 T-C Non-coding Unpublished
2260 1 A-C Non-coding Unpublished
2306 1 A-T Non-coding Unpublished
2706 15 A-G Non-coding *+
2707 1 A-C Non-coding +
2778 1 T-C Non-coding Unpublished
2805 1 A-T Non-coding Unpublished
3010 3 G-A Non-coding *+
3107 26 N-T rCRcorrection *+
3170 1 C-A Non-coding Unpublished
3197 2 T-C Non-coding +
3202 1 T-C Non-coding +
TL1 3285 2 T-C Non-coding *+
ND1 3338 1 T-C V-A *+
3392 1 G-C G-A +
3480 2 A-G Syn +
TQ 4384 1 T-C ?????? Unpublished
ND2 4529 1 A-T Syn +
4646 2 T-C Syn +
4655 1 G-A Syn +
4823 1 T-C Syn +
4917 2 A-G N-D +
5021 1 T-C Syn Unpublished
5046 3 G-A V-A +
5460 4 G-A A-T +
5480 1 A-G Syn +
5495 1 T-C Syn +
CO2 8251 1 G-A Syn +
ATP6 8614 3 T-C Syn +
8682 1 A-G Syn Unpublished
8648 1 G-A R-Q +
8697 2 G-A Syn +
8701 2 A-G T-A *+
8705 1 T-C M-T +
8860 30 A-G T-A *+
8994 1 G-A Syn +
S-N
Table IV. Frequency of some polymorphisms among Iranian HCM patients
Reported among HCM patients before. rCRcorrection: http://www.mitomap.org/mitoseq.html
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nucleotide 9997 in a maternally affected inherited
HC [16]. Only T4384C mutation was found in tRNA
glutamine that affects the T_C loop among our
patients. As this mutation has not been reported
before, more investigation is needed to specify it
accurately. 
Unreported base substitutions in mtDNA were
found in this study. Whereas the “silent” ones, i.e.,
not affecting amino acid composition of the
encoded polypeptide, are generally assumed to
represent polymorphism, the role of the others is
less obvious. 
An A-to-G transition at nucleotides 8860,
previously characterized, was present in a high
proportion (30 of 31 patients) in our study with
respect to the Cambridge Reference Sequence [17].
While this polymorphism was found among
idiopathic cardiomyopathic patients, it was
considered as a possible error in the Cambridge
sequence but future studies showed that it is a rare
polymorphism [18]. In fact none of our 60 controls
showed this polymorphism. Some other studies
have found this transition in a high proportion, such
as all 79 patients with Alzheimer’s disease [19], all
23 patients affected with bipolar affective disorder
[20], and 13/14 patients with Leber’s hereditary
optic neuropathy [21]. These findings suggest that
this polymorphism may a have close relation with
these kinds of mitochondrial degenerative diseases.
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